Copenhagen Conference: Legal Perspectives on Synthetic Biology and Gene Editing

Join us at the Centre for Information and Innovation Law (CIIR) Faculty of Law, University of Copenhagen on 20 November, 2017 to discuss Legal Perspectives on Synthetic Biology and Gene Editing.


Emerging technologies in Synthetic Biology and Gene Editing offer incredible opportunities and promising solutions to some of the most urgent challenges faced by humanity, such as climate change, environmental protection, growing population, renewable energy and improved health care. But the emerging applications also raise exceptional ethical, legal and social questions.

This conference marks the final phase of the participation of the Copenhagen Biotech and Pharma Forum (CBPF) Research Group at the Centre for Information and Innovation Law (CIIR) in the cross-faculty research project BioSYNergy. In accordance with the goals of this large cross-faculty project on Synthetic Biology, the event explores legal perspectives on synthetic biology, systems biology and gene editing. Dealing with the legal responses to ethical and scientific challenges raised by emerging life science technology.

Taking into account the newest scientific developments and challenges, invited speakers will debate the legal implications of bio-pharma innovation in synthetic biology and gene editing. The conference will explore interfaces between Law, Science, Ethics and Commercialization of Bio-pharma innovation, with a focus on:

  • Gene editing regulation and applications
  • IP and Innovation
  • Licensing and Collaboration
  • Ethics and Human Enhancement

Abstracts (max 500 words) to be submitted until 13 September 2017 to:

An edited volume based on the conference proceedings is being projected, selected speakers will be invited to contribute with a chapter (8,000-10,000 words incl. footnotes and bibliography).

Early expressions of interest or full paper submissions are most welcome.

Organizers: Postdoctoral Fellow Ana Nordberg; Prof. Timo Minssen; Research Fellow Jakob Wested


*Final date to be announced.

The event is free to attend. Registration is mandatory. Please use this registration form no later than Thursday, 16 November 2017 at the latest.

This entry was posted in Announcements, Bioethics, Biotechnology, Call for Abstracts, Clinical Research, Cloning, Enhancement, Global Health, GMO Food, Human Tissue, Intellectual Property, Pharmaceuticals, Public Health, Reproductive Technology, Stem Cells, Timo Minssen, Vaccines and tagged , , , , , by Timo Minssen. Bookmark the permalink.

About Timo Minssen

Timo Minssen is Professor of Law specializing in legal aspects of biomedical innovation at the University of Copenhagen (UCPH). He is the Managing Director and Founder of UCPH's new Center for Advanced Studies and Collaborative Research Programme in Biomedical Innovation Law (CeBIL). Previously, Timo had been Professor of Biotechnology Law at UCPH's Centre for Information & Innovation Law (CIIR), Visiting Research Fellow at the Universities of Cambridge and Oxford (UK), Harvard Law School and at the Chicago-Kent College of Law (US), as well as Max Planck stipendiate at the Max Planck Institute for Innovation & Competition in Munich (Germany). Moreover, he was trained in the German Court system (Referendariat) and worked for shorter periods at the European Patent Office (EPO), leading law firms, tech start-ups and and for an interdisciplinary epigenetics project as a fellow of the Swedish Pufendorf Institute for Advanced Studies.. Timo holds a German law degree (Staatsexamen) from Georg-August-University in Göttingen, as well as Swedish biotech & IPR related LL.M., LL.Lic., and LL.D. degrees from Lund University and Uppsala University. His PhD thesis delivered a comprehensive study on the patentability of biopharmaceutical technology in the US & Europe, which received the Swedish King Oscar award. He has also received the Awapatent and Jorcks Foundation Research Prizes and was a finalist of the Swedish Wallenberg Academy Fellows program.